Loading company
Inogen Inc
INGN · Nasdaq · ·
Next earnings: November 4, 2026
$5.36-1.5%Sep 29 close
- 1M
- -2.5%
- 6M
- -12.3%
- 1Y
- -34.4%
- 5Y
- -88.5%
INGN · Nasdaq · ·
Next earnings: November 4, 2026
$5.36-1.5%Sep 29 close
Inogen Inc is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $95.1M | $92.3M | +3.04% |
| Profit | -$3.9M | -$4.2M | +7.27% |
| Profit per share | -$0.14 | -$0.15 | +6.67% |
| Free Cash Flow | $2.2M | $3.7M | -39.03% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter results demonstrate continued demand for our products and validate the progress of our strategy to expand and diversify Inogen’s respiratory care portfolio,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Inogen Inc’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Inogen Inc has no earnings call transcript available.